Current Report Filing (8-k)
March 29 2017 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 29, 2017
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-32979
|
94-3409596
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip
Code)
(650) 474-8200
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure.
|
Spokespersons of Threshold Pharmaceuticals,
Inc. (the “Company”) plan to present the information in the presentation slides attached hereto as Exhibit 99.1.
The furnishing of the attached
presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary
information that is intended to be considered in the context of more complete information included in the Company’s filings
with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made
and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise
the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any
such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other
public disclosures. For important information about forward looking statements, see the slide titled “Forward Looking Statements”
in Exhibit 99.1 attached hereto.
The information in this Item 7.01
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation attached
as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company,
whether made before or after the date hereof, regardless of any general incorporation language in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit
No.
|
|
Description
|
99.1
|
|
Company slide presentation
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
THRESHOLD PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Joel A. Fernandes
|
|
|
|
Joel A. Fernandes
|
|
|
|
Senior Vice President, Finance and Controller
|
|
Date: March 29, 2017
THRESHOLD PHARMACEUTICALS, INC.
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Company slide presentation
|
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Sep 2023 to Sep 2024